CAR T-Cell therapy in the UK

[Shar0n]

"The National Institute for Health and Care Excellence (NICE) issued draft guidance.. that said tisagenlecleucel (Kymriah, Novartis) — which is approved in the United States and European Union — is too expensive to justify its use in England’s National Health Service (NHS) for adults with lymphoma." Hopefully this will change as when these therapies work they appear to be very effective.

tinyurl.com/ybkq85do